MX2016004629A - Compuestos de quinolina selectivamente sustituidos. - Google Patents
Compuestos de quinolina selectivamente sustituidos.Info
- Publication number
- MX2016004629A MX2016004629A MX2016004629A MX2016004629A MX2016004629A MX 2016004629 A MX2016004629 A MX 2016004629A MX 2016004629 A MX2016004629 A MX 2016004629A MX 2016004629 A MX2016004629 A MX 2016004629A MX 2016004629 A MX2016004629 A MX 2016004629A
- Authority
- MX
- Mexico
- Prior art keywords
- selectively substituted
- substituted quinoline
- quinoline compounds
- sle
- toll
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 102000002689 Toll-like receptor Human genes 0.000 abstract 1
- 108020000411 Toll-like receptor Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las modalidades de la descripción se refieren a compuestos de quinolina selectivamente sustituidos que actúan como antagonistas o inhibidores para receptores tipo Toll 7 y/u 8, y su uso en composiciones farmacéuticas efectivas para el tratamiento de lupus eritematoso sistémico (SLE) y nefritis lúpica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361890858P | 2013-10-14 | 2013-10-14 | |
PCT/US2014/060412 WO2015057655A1 (en) | 2013-10-14 | 2014-10-14 | Selectively substituted quinoline compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016004629A true MX2016004629A (es) | 2016-08-01 |
MX363708B MX363708B (es) | 2019-03-29 |
Family
ID=51842880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004629A MX363708B (es) | 2013-10-14 | 2014-10-14 | Compuestos de quinolina selectivamente sustituidos. |
Country Status (13)
Country | Link |
---|---|
US (1) | US9663486B2 (es) |
EP (1) | EP3057948B1 (es) |
JP (1) | JP6483666B2 (es) |
KR (1) | KR102365952B1 (es) |
CN (2) | CN107935988A (es) |
AU (1) | AU2014334551B2 (es) |
BR (1) | BR112016008378B1 (es) |
CA (1) | CA2920791C (es) |
ES (1) | ES2670550T3 (es) |
IL (2) | IL243926B (es) |
MX (1) | MX363708B (es) |
RU (1) | RU2671496C2 (es) |
WO (1) | WO2015057655A1 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9139568B2 (en) * | 2011-12-22 | 2015-09-22 | Merck Patent Gmbh | Heterocyclic carboxamides as modulators of kinase activity |
MA39034B1 (fr) | 2013-10-14 | 2018-09-28 | Eisai R&D Man Co Ltd | Composés de quinoline sélectivement substitués |
US9663486B2 (en) | 2013-10-14 | 2017-05-30 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
SG11201804170RA (en) * | 2015-12-17 | 2018-06-28 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
EP3497094B1 (en) * | 2016-08-08 | 2023-02-15 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
CU24526B1 (es) | 2016-09-09 | 2021-06-08 | Novartis Ag | Compuestos inhibidores de los receptores endosomales tipo peaje |
US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
JP7239554B2 (ja) * | 2017-07-18 | 2023-03-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tlr7/8アンタゴニストおよびそれらの使用 |
EP3728229A1 (en) * | 2017-12-19 | 2020-10-28 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド |
WO2019123294A2 (en) * | 2017-12-22 | 2019-06-27 | Novartis Ag | Novel uses of pyrazolo piperidine derivatives |
EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
JP7434186B2 (ja) | 2018-06-12 | 2024-02-20 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のヘテロアリールヘテロシクリル化合物 |
US20210269451A1 (en) * | 2018-06-13 | 2021-09-02 | Hoffmann-La Roche Inc. | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
JPWO2020017569A1 (ja) * | 2018-07-17 | 2021-12-02 | 日本ケミファ株式会社 | T型カルシウムチャネル阻害剤 |
JP7366994B2 (ja) * | 2018-07-23 | 2023-10-23 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
CA3108099A1 (en) * | 2018-07-31 | 2020-02-06 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
JP7233809B2 (ja) | 2018-09-04 | 2023-03-07 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のためのベンゾチアゾール化合物 |
JP2022502353A (ja) * | 2018-09-06 | 2022-01-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の処置のための新規の環状アミジン化合物 |
US20210355122A1 (en) * | 2018-09-06 | 2021-11-18 | Hoffmann-La Roche Inc. | Pyrazolopyridine compounds for the treatment of autoimmune disease |
EP3847165A1 (en) * | 2018-09-07 | 2021-07-14 | F. Hoffmann-La Roche AG | Novel pyrrolidine amine compounds for the treatment of autoimmune disease |
SG11202103839UA (en) | 2018-10-31 | 2021-05-28 | Gilead Sciences Inc | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
AU2019373221B2 (en) | 2018-10-31 | 2022-05-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity |
US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
US10689360B1 (en) | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
CA3135344A1 (en) * | 2019-03-29 | 2020-10-08 | Nippon Chemiphar Co., Ltd. | Use of t-type calcium channel blocker for treating pruritus |
JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
WO2021048200A1 (en) | 2019-09-10 | 2021-03-18 | F. Hoffmann-La Roche Ag | Novel quinoline compounds for the treatment of autoimmune disease |
CN114401954A (zh) | 2019-09-16 | 2022-04-26 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的哌啶基胺化合物 |
IL291590B2 (en) * | 2019-09-23 | 2023-11-01 | Accutar Biotechnology Inc | Novel modified quinoline-8-carbonitrile compounds with androgen receptor unblocking activity and their uses |
BR112022005687A2 (pt) | 2019-09-30 | 2022-06-21 | Gilead Sciences Inc | Vacinas contra o hbv e métodos para tratar o hbv |
EP4058452A1 (en) * | 2019-11-12 | 2022-09-21 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
US20230022297A1 (en) * | 2019-12-03 | 2023-01-26 | Hoffmann-La Roche Inc. | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
CN112649540B9 (zh) * | 2021-01-11 | 2022-02-18 | 中国科学院西北生态环境资源研究院 | 一种类异戊二烯烷烃中姥鲛烷非对映异构体快速分离方法 |
WO2022194237A1 (zh) * | 2021-03-18 | 2022-09-22 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在制备自身免疫药物上的应用 |
MX2023012110A (es) | 2021-04-16 | 2023-10-24 | Gilead Sciences Inc | Compuestos de tienopirrol. |
KR20240006683A (ko) | 2021-05-13 | 2024-01-15 | 길리애드 사이언시즈, 인코포레이티드 | TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022297367A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
CN117957234A (zh) | 2021-09-10 | 2024-04-30 | 吉利德科学公司 | 噻吩并吡咯化合物 |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO156828C (no) | 1980-11-10 | 1987-12-02 | Otsuka Pharma Co Ltd | Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser. |
IL62783A (en) | 1981-05-04 | 1987-01-30 | Usv Pharma Corp | Antihypertensive 1,4-thiazine,1,4-thiazepine and 1,4-thiazocine compounds,method for the preparation thereof and pharmaceutical compositions containing the same |
JPS5890511A (ja) | 1981-11-25 | 1983-05-30 | Otsuka Pharmaceut Co Ltd | 抗菌剤 |
US5358949A (en) | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
JPS6354363A (ja) | 1986-08-26 | 1988-03-08 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
AU639529B2 (en) | 1987-03-04 | 1993-07-29 | Higuchi, Yoshinari | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
JPH01156960A (ja) * | 1987-09-24 | 1989-06-20 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
JPH08295690A (ja) | 1995-04-26 | 1996-11-12 | Tokuyama Corp | クロメン化合物 |
DE69738907D1 (de) | 1996-10-11 | 2008-09-25 | Kowa Co | Neue diamidverbindungen und medikamente die diese enthalten |
DE19643048A1 (de) | 1996-10-18 | 1998-04-23 | Daimler Benz Ag | Verbindungen und deren Verwendung sowie Verfahren zur Herstellung von flüssigkristallinen Polymeren daraus |
GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
US6933272B1 (en) | 1998-09-22 | 2005-08-23 | Erik Helmerhorst | Use of non-peptidyl compounds for the treatment of insulin related ailments |
SK15522001A3 (sk) | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
JP4598278B2 (ja) | 1999-04-28 | 2010-12-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppar受容体リガンドとしてのジアリール酸誘導体 |
DE19936437A1 (de) | 1999-08-03 | 2001-02-08 | Aventis Cropscience Gmbh | Kombinationen aus Herbiziden und Safenern |
FR2798656B1 (fr) * | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
US6710205B2 (en) | 2000-02-22 | 2004-03-23 | Ono Pharmaceutical Co., Ltd. | Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient |
EP1263755A2 (en) | 2000-03-17 | 2002-12-11 | Bristol-Myers Squibb Pharma Company | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
AU2001250850A1 (en) | 2000-03-17 | 2001-10-03 | Dupont Pharmaceuticals Company | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
WO2002018335A1 (fr) | 2000-08-28 | 2002-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'amine cyclique |
US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
EP1317442B1 (en) | 2000-09-11 | 2005-11-16 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
EP1371376A4 (en) | 2001-03-19 | 2009-03-25 | Nippon Shinyaku Co Ltd | Antipruritic agents |
US20030055263A1 (en) | 2001-07-11 | 2003-03-20 | Boehringer Ingelheim Pharma Kg | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
BR0212510A (pt) | 2001-09-14 | 2004-08-24 | Methylgene Inc | Inibidor de histona desacetilase, composto e composição |
DE10222166A1 (de) | 2002-05-20 | 2003-12-11 | Fraunhofer Ges Forschung | Chirale Verbindungen und deren Verwendung |
DE10229070A1 (de) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
JP3908248B2 (ja) | 2002-08-13 | 2007-04-25 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有するヘテロ環化合物 |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
JP4613130B2 (ja) | 2002-08-23 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | ベンゾイミダゾールキノリノンおよびそれらの使用 |
US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
US7041693B2 (en) | 2002-10-04 | 2006-05-09 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
WO2004032846A2 (en) | 2002-10-07 | 2004-04-22 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
US20040072802A1 (en) | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
GB2396154B (en) | 2002-10-15 | 2007-02-28 | Merck Patent Gmbh | 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices |
KR20050109505A (ko) | 2003-02-22 | 2005-11-21 | 메르크 파텐트 게엠베하 | 액정인 시아노피리돈 유도체 |
WO2004083235A2 (en) | 2003-03-19 | 2004-09-30 | Exelixis Inc. | Tie-2 modulators and methods of use |
WO2004087698A2 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
WO2004087835A1 (en) | 2003-04-01 | 2004-10-14 | Merck Patent Gmbh | Chiral polymerizable compounds |
CN1809357B (zh) * | 2003-06-20 | 2010-12-22 | 科勒制药有限公司 | 小分子Toll样受体(TLR)拮抗剂 |
MXPA05013922A (es) | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
WO2005028488A1 (en) | 2003-09-12 | 2005-03-31 | Quatrx Pharmaceuticals Co. | Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels |
US7211671B2 (en) | 2003-10-01 | 2007-05-01 | Bristol Myers Squibb Company | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
JP2005132834A (ja) | 2003-10-09 | 2005-05-26 | Kyowa Hakko Kogyo Co Ltd | キノリン誘導体 |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
CA2543820C (en) | 2003-11-07 | 2012-07-10 | Chiron Corporation | Methods for synthesizing quinolinone compounds |
TWI316955B (en) | 2003-11-19 | 2009-11-11 | Chisso Corp | Photo-polymerization liquid composition,polymer or polymer co mposition and optical compensation device thereof |
US20080227772A1 (en) | 2004-02-04 | 2008-09-18 | Neurosearch A/S | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands |
EA200601266A1 (ru) | 2004-02-18 | 2007-02-27 | Астразенека Аб | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
US7875624B2 (en) | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
US8404747B2 (en) | 2004-03-05 | 2013-03-26 | The General Hospital Corporation | Compositions and methods for modulating interaction between polypeptides |
JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
US7268232B2 (en) | 2004-05-17 | 2007-09-11 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
WO2005111033A2 (en) | 2004-05-19 | 2005-11-24 | Neurosearch A/S | Novel azabicyclic aryl derivatives |
GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
US20080306055A1 (en) | 2004-12-21 | 2008-12-11 | Astrazeneca Ab | Heterocyclic Mchr1 Antagonists And Their Use In Therapy |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
WO2006110276A2 (en) | 2005-04-08 | 2006-10-19 | Cropsolution, Inc. | Acylated thiosemicarbazides as herbicides |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
JP2007045752A (ja) | 2005-08-10 | 2007-02-22 | Takeda Chem Ind Ltd | 5員芳香族複素環誘導体、その製造法および用途 |
JP2007131765A (ja) | 2005-11-11 | 2007-05-31 | Fujifilm Corp | 液晶性組成物 |
AU2006330924B2 (en) | 2005-12-21 | 2012-03-15 | Abbvie Inc. | Anti-viral compounds |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
US20100222353A1 (en) | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
MX2009000310A (es) | 2006-07-14 | 2009-01-26 | Novartis Ag | Derivados de pirimidina como inhibidores de alk-5. |
TW200817410A (en) | 2006-08-07 | 2008-04-16 | Incyte Corp | Triazolotriazines as kinase inhibitors |
EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
JP5380296B2 (ja) | 2006-11-17 | 2014-01-08 | ポリエラ コーポレイション | ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法 |
DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
CA2682504C (en) | 2007-04-05 | 2012-10-30 | Amgen Inc. | Aurora kinase modulators and method of use |
WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US8173639B2 (en) | 2007-04-26 | 2012-05-08 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
WO2008156783A2 (en) | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Family of pfkfb3 inhibitors with anti-neoplastic activities |
US8557823B2 (en) | 2007-06-18 | 2013-10-15 | Advanced Cancer Therapeutics, Llc | Family of PFKFB3 inhibitors with anti-neoplastic activities |
JP2010530416A (ja) | 2007-06-20 | 2010-09-09 | メルク・シャープ・エンド・ドーム・コーポレイション | ベンゾオキサゾールアリールアミドから誘導されたcetp阻害剤 |
AU2008266956A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | CETP inhibitors derived from benzoxazole arylamides |
JP5057056B2 (ja) | 2007-08-03 | 2012-10-24 | Jsr株式会社 | 液晶配向剤、液晶配向膜の製造方法、ポリアミック酸およびポリイミドならびにジアミン化合物 |
JP2011502158A (ja) | 2007-10-29 | 2011-01-20 | シェーリング コーポレイション | プロテインキナーゼ阻害剤としてのジアミドチアゾール誘導体 |
JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
CN101440062B (zh) | 2007-11-23 | 2011-09-28 | 齐齐哈尔大学 | N-酰基-8-氨基喹啉衍生物的合成及其作为荧光分子探针的应用 |
JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
JP2011514898A (ja) | 2008-03-07 | 2011-05-12 | エフ.ホフマン−ラ ロシュ アーゲー | 2−アミノキノリン誘導体 |
JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
US8980877B2 (en) | 2008-04-15 | 2015-03-17 | Dac S.R.L. | Spirocyclic derivatives as histone deacetylase inhibitors |
US8703811B2 (en) | 2008-05-07 | 2014-04-22 | Genzyme Corporation | Small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase |
WO2009139438A1 (ja) | 2008-05-15 | 2009-11-19 | 田辺三菱製薬株式会社 | 光学活性カルボン酸の製造方法 |
AU2009257795A1 (en) | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of FAAH |
CA2727245A1 (en) | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Imidazole derivatives useful as inhibitors of faah |
BRPI0915205A2 (pt) | 2008-06-11 | 2017-03-21 | Dana Farber Cancer Inst Inc | compostos e composições úteis para o tratamento de malária |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
EP3289876B1 (en) | 2008-06-16 | 2022-07-20 | University of Tennessee Research Foundation | Compounds for treatment of cancer |
KR20110050623A (ko) | 2008-07-15 | 2011-05-16 | 타이젠 바이오테크놀러지 컴퍼니 리미티드 | 항생제 |
WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
MX2011001313A (es) | 2008-08-04 | 2011-03-04 | Merck Sharp & Dohme | Derivados de oxazol utiles como inhibidores de la amida hidrolasa de acidos grasos. |
AR073010A1 (es) | 2008-08-12 | 2010-10-06 | Takeda Pharmaceutical | Compuesto amida con actividad agonista del gpr52 |
JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
EP2350068B1 (en) | 2008-10-23 | 2017-08-30 | Boehringer Ingelheim International GmbH | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |
US8987242B2 (en) | 2008-12-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXA inhibitors |
US8642582B2 (en) | 2008-12-05 | 2014-02-04 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXa inhibitors |
MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
JP2012513409A (ja) | 2008-12-23 | 2012-06-14 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
CN101759683B (zh) | 2008-12-25 | 2011-12-28 | 哈尔滨誉衡药业股份有限公司 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する複素環化合物 |
JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
CN101838264B (zh) | 2009-03-16 | 2014-12-03 | 住友化学株式会社 | 化合物、光学膜和光学膜的制造方法 |
JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
US20110021531A1 (en) | 2009-07-27 | 2011-01-27 | Chobanian Harry | Oxazole derivatives useful as inhibitors of faah |
US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
ES2433230T3 (es) | 2009-08-06 | 2013-12-10 | Merck Patent Gmbh | Compuestos bicíclicos novedosos de urea |
JP2011042606A (ja) | 2009-08-20 | 2011-03-03 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
WO2011025706A2 (en) | 2009-08-26 | 2011-03-03 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
JP2013503163A (ja) | 2009-08-31 | 2013-01-31 | 持田製薬株式会社 | 第IXa因子阻害薬としてのモルホリノン化合物 |
CA2773848A1 (en) | 2009-09-09 | 2011-03-17 | Avila Therapeutics, Inc. | Pi3 kinase inhibitors and uses thereof |
WO2011029842A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
CN102686551B (zh) | 2009-12-01 | 2014-11-12 | 住友化学株式会社 | 环烷二羧酸单酯的制造方法 |
MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
AU2011205283B2 (en) | 2010-01-13 | 2014-07-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
MX2012008801A (es) | 2010-01-28 | 2012-08-17 | Merck Sharp & Dohme | Composiciones farmaceuticas para el tratamiento de dolor y otras indicaciones. |
EP2533639A4 (en) | 2010-02-11 | 2013-08-21 | Univ Vanderbilt | COMPOUNDS OF PYRAZOLOPYRIDINE, PYRAZOLOPYRAZINE, PYRAZOLOPYRIMIDINE, PYRAZOLOTHIOPHENE AND PYRAZOLOTHIAZOLE AS ALLOSTERIC POTENTIALIZERS OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 4 (MGLUR4), COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
RU2581367C2 (ru) | 2010-03-01 | 2016-04-20 | Джи Ти Икс, ИНК. | Соединения для лечения рака |
JP5871897B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジルトリアゾール |
US9290507B2 (en) | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
JP5856606B2 (ja) | 2010-04-22 | 2016-02-10 | メルク・シャープ・エンド・ドーム・コーポレイション | Faahの調節薬として有用なオキサゾール誘導体 |
JP2013525368A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
EP2560657B1 (en) | 2010-04-23 | 2015-09-16 | Kineta, Inc. | Diarylpyridine anti-viral compounds |
US20120149715A1 (en) | 2010-05-28 | 2012-06-14 | Yi Tsun Richard Kao | Compounds and methods for the treatment of viral infections |
JP5652011B2 (ja) | 2010-06-10 | 2015-01-14 | 住友化学株式会社 | 光学フィルム |
WO2012009194A1 (en) | 2010-07-12 | 2012-01-19 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
EP2609092B1 (en) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
KR101513234B1 (ko) | 2010-09-10 | 2015-04-17 | 주식회사 녹십자 | Sglt2 억제제로서의 신규 티오펜 유도체 및 이를 포함하는 약학 조성물 |
WO2012052540A1 (en) | 2010-10-21 | 2012-04-26 | Universitaet Des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
WO2012084219A1 (en) | 2010-12-23 | 2012-06-28 | Solvay Sa | Preparation of a fac-isomer for a tris homoleptic metal complex |
US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
EP2686325B1 (en) | 2011-03-14 | 2016-12-14 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
CN102675289B (zh) | 2011-03-18 | 2014-11-05 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物 |
WO2012128582A2 (en) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
CA2840883C (en) | 2011-07-07 | 2019-07-16 | Merck Patent Gmbh | Substituted azaheterocycles |
WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
WO2013009830A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
US9682953B2 (en) | 2011-09-23 | 2017-06-20 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
MA39034B1 (fr) | 2013-10-14 | 2018-09-28 | Eisai R&D Man Co Ltd | Composés de quinoline sélectivement substitués |
US9663486B2 (en) | 2013-10-14 | 2017-05-30 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
-
2014
- 2014-10-14 US US14/908,164 patent/US9663486B2/en active Active
- 2014-10-14 EP EP14790936.0A patent/EP3057948B1/en active Active
- 2014-10-14 ES ES14790936.0T patent/ES2670550T3/es active Active
- 2014-10-14 CN CN201710963307.5A patent/CN107935988A/zh active Pending
- 2014-10-14 AU AU2014334551A patent/AU2014334551B2/en active Active
- 2014-10-14 CN CN201480056216.8A patent/CN105636945B/zh active Active
- 2014-10-14 WO PCT/US2014/060412 patent/WO2015057655A1/en active Application Filing
- 2014-10-14 MX MX2016004629A patent/MX363708B/es unknown
- 2014-10-14 RU RU2016118624A patent/RU2671496C2/ru active
- 2014-10-14 BR BR112016008378-4A patent/BR112016008378B1/pt active IP Right Grant
- 2014-10-14 CA CA2920791A patent/CA2920791C/en active Active
- 2014-10-14 KR KR1020167009292A patent/KR102365952B1/ko active IP Right Grant
- 2014-10-14 JP JP2016516866A patent/JP6483666B2/ja active Active
-
2016
- 2016-02-03 IL IL243926A patent/IL243926B/en active IP Right Grant
-
2019
- 2019-06-02 IL IL267031A patent/IL267031B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20160068775A (ko) | 2016-06-15 |
IL243926B (en) | 2019-06-30 |
EP3057948A1 (en) | 2016-08-24 |
MX363708B (es) | 2019-03-29 |
JP6483666B2 (ja) | 2019-03-13 |
IL267031B (en) | 2021-05-31 |
WO2015057655A1 (en) | 2015-04-23 |
RU2016118624A (ru) | 2017-11-17 |
US9663486B2 (en) | 2017-05-30 |
KR102365952B1 (ko) | 2022-02-22 |
RU2016118624A3 (es) | 2018-04-25 |
RU2671496C2 (ru) | 2018-11-01 |
IL243926A0 (en) | 2016-04-21 |
EP3057948B1 (en) | 2018-03-14 |
JP2016539079A (ja) | 2016-12-15 |
ES2670550T3 (es) | 2018-05-30 |
CN105636945B (zh) | 2017-11-17 |
BR112016008378A2 (es) | 2017-10-03 |
AU2014334551B2 (en) | 2018-05-10 |
IL267031A (en) | 2019-07-31 |
CN105636945A (zh) | 2016-06-01 |
BR112016008378B1 (pt) | 2022-11-08 |
CN107935988A (zh) | 2018-04-20 |
US20160176841A1 (en) | 2016-06-23 |
CA2920791A1 (en) | 2015-04-23 |
CA2920791C (en) | 2021-11-16 |
AU2014334551A1 (en) | 2016-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500522A1 (en) | Tetrahydropyrazolopyrimidine compounds | |
MX2019005192A (es) | Compuestos de quinolina selectivamente sustituida. | |
MX2016004629A (es) | Compuestos de quinolina selectivamente sustituidos. | |
MY179781A (en) | Biaryl inhibitors of bruton's tyrosine kinase | |
PH12015502141A1 (en) | Substituted xanthines and methods of use thereof | |
AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
EA201490806A1 (ru) | Комбинированный состав двух противовирусных соединений | |
NZ716840A (en) | Combination formulation of two antiviral compounds | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
IN2013MU03641A (es) | ||
MA39824A (fr) | Composés azole amido-substitués | |
IN2013MU02610A (es) | ||
LV15016A (lv) | N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas |